{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:46:05Z","timestamp":1784184365981,"version":"3.55.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Prescription stimulants are an effective FDA approved treatment for attention deficit hyperactivity disorder (ADHD) however their safety has come under scrutiny. Multiple studies demonstrate safe use in pediatric populations, but prescriptions are increasing to adults and it is not evident which comorbidities might place people at risk of adverse outcomes. The aim of this study is to identify risk factors of adverse cardiovascular events for individuals exposed to stimulants across the lifespan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a case control study utilizing the TriNetX research network database. Individuals were included for study if they were younger than 90\u2009years old and prescribed stimulants between January 1, 2010 and December 31, 2020. We utilized summary statistics, chi2, and multivariate logistic regression to identify risk factors for cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 987,762 individuals prescribed stimulants, 49,902 experienced an adverse cardiovascular event. Individuals with atherosclerotic heart disease had the highest odds of adverse events (aOR\u2009=\u200936.7,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001). Hypertension (aOR\u2009=\u20092.78\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001), cocaine use (aOR\u2009=\u20091.64\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001), and anxiety (aOR\u2009=\u20091.46\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.001) were also strongly predictive of adverse outcomes, but risk varied by age.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Atherosclerotic heart disease and its antecedents pose the greatest risk for cardiovascular events for people prescribed stimulants. Mental health diagnoses are also independent predictors and age may be an effect modifier of these relationships. ADHD was not an independent risk factor for major adverse cardiovascular events when controlling for other biopsychosocial variables in adult populations. Additional research focused on predictive models and prospective studies may be warranted to better inform clinical decisions regarding stimulant prescriptions for the broad demographic of patients that may benefit from these medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10870547251313880","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:00:39Z","timestamp":1739170839000},"page":"628-634","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk Factors for Adverse Cardiac Events in Individuals Prescribed Stimulants Across the Lifespan"],"prefix":"10.1177","volume":"29","author":[{"given":"Destin","family":"Groff","sequence":"first","affiliation":[{"name":"Penn State College of Medicine, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3939-8979","authenticated-orcid":false,"given":"Wen-Jan","family":"Tuan","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kraig","family":"Holt","sequence":"additional","affiliation":[{"name":"The United States Department of Defense, Federal Government office building, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Latronica","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Bone","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Health Science Center San Antonio, San Antonio, TX, USA"},{"name":"Department of Family and Community Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Arnsten A. F. T. (2006). Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31(11) 2376\u20132383. https:\/\/doi.org\/10.1038\/sj.npp.1301164","DOI":"10.1038\/sj.npp.1301164"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Brumbaugh S. Tuan W. J. Scott A. Latronica J. R. Bone C. (2022). Trends in characteristics of the recipients of new prescription stimulants between years 2010 and 2020 in the United States: An observational cohort study. EClinicalMedicine 50 Article 101524. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101524","DOI":"10.1016\/j.eclinm.2022.101524"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Chang Z. Lichtenstein P. Halldner L. D\u2019Onofrio B. Serlachius E. Fazel S. L\u00e5ngstr\u00f6m N. Larsson H. (2014). Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry and Allied Disciplines 55(8) 878\u2013885. https:\/\/doi.org\/10.1111\/jcpp.12164","DOI":"10.1111\/jcpp.12164"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Charatan F. (2006). FDA committee votes for warning labels on stimulant drugs. BMJ (Clinical Research Ed.) 332(7538) 380. https:\/\/doi.org\/10.1136\/bmj.332.7538.380-a","DOI":"10.1136\/bmj.332.7538.380-a"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Choi S. Baudot M. Vivas O. Moreno C. M. (2022). Slowing down as we age: Aging of the cardiac pacemaker\u2019s neural control. GeroScience 44(1) 1\u201317. https:\/\/doi.org\/10.1007\/s11357-021-00420-3","DOI":"10.1007\/s11357-021-00420-3"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Danielson M. L. Bitsko R. H. Ghandour R. M. Holbrook J. R. Kogan M. D. Blumberg S. J. (2018). Prevalence of parent-reported ADHD diagnosis and associated treatment among U.S. children and adolescents 2016. Journal of Clinical Child and Adolescent Psychology 47(2) 199\u2013212. https:\/\/doi.org\/10.1080\/15374416.2017.1417860","DOI":"10.1080\/15374416.2017.1417860"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Hardy S. E. (2009). Methylphenidate for the treatment of depressive symptoms including fatigue and apathy in medically ill older adults and terminally ill adults. The American Journal of Geriatric Pharmacotherapy 7(1) 34\u201359. https:\/\/doi.org\/10.1016\/j.amjopharm.2009.02.006","DOI":"10.1016\/j.amjopharm.2009.02.006"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Hechtman L. Abikoff H. Klein R. G. Weiss G. Respitz C. Kouri J. Blum C. Greenfield B. Etcovitch J. Fleiss K. Pollack S. (2004). Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry 43(7) 812\u2013819. https:\/\/doi.org\/10.1097\/01.chi.0000128796.84202.eb","DOI":"10.1097\/01.chi.0000128796.84202.eb"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Hennissen L. Bakker M. J. Banaschewski T. Carucci S. Coghill D. Danckaerts M. Dittmann R. W. Hollis C. Kovshoff H. McCarthy S. Nagy P. Sonuga-Barke E. Wong I. C. K. Zuddas A. Rosenthal E. Buitelaar J. K. ADDUCE consortium. (2017). Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: A systematic review and meta-analysis of trials of methylphenidate amphetamines and atomoxetine. CNS Drugs 31(3) 199\u2013215. https:\/\/doi.org\/10.1007\/s40263-017-0410-7","DOI":"10.1007\/s40263-017-0410-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Latronica J. R. Clegg T. J. Tuan W.-J. Bone C. (2021). Are amphetamines associated with adverse cardiovascular events among elderly individuals? Journal of the American Board of Family Medicine: JABFM 34(6) 1074\u20131081. https:\/\/doi.org\/10.3122\/jabfm.2021.06.210228","DOI":"10.3122\/jabfm.2021.06.210228"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Latronica J. R. Tuan W. J. Clegg T. J. Silvis M. L. Bone C. (2022). Cardiovascular outcomes among older individuals with depression prescribed amphetamines: A retrospective cohort study. The Journals of Gerontology. Series A Biological Sciences and Medical Sciences 27 2459\u20132463. https:\/\/doi.org\/10.1093\/gerona\/glac033","DOI":"10.1093\/gerona\/glac033"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Li L. Zhu N. Zhang L. Kuja-Halkola R. D\u2019Onofrio B. M. Brikell I. Lichtenstein P. Cortese S. Larsson H. Chang Z. (2024). ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA 331(10) 850\u2013860. https:\/\/doi.org\/10.1001\/jama.2024.0851","DOI":"10.1001\/jama.2024.0851"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Lim F. Bellows B. K. Tan S. X. Aziz Z. Woo Baidal J. A. Kelly A. S. Hur C. (2023). Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents. JAMA Network Open 6(8) e2329178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29178","DOI":"10.1001\/jamanetworkopen.2023.29178"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Olfson M. Blanco C. Wang S. Greenhill L. L. (2013). Trends in office-based treatment of adults with stimulants in the United States. The Journal of Clinical Psychiatry 74(1) 43\u201350. https:\/\/doi.org\/10.4088\/JCP.12m07975","DOI":"10.4088\/JCP.12m07975"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Piper B. J. Ogden C. L. Simoyan O. M. Chung D. Y. Caggiano J. F. Nichols S. D. McCall K. L. (2018). Trends in use of prescription stimulants in the United States and Territories 2006 to 2016. PLoS ONE 13(11) e0206100. https:\/\/doi.org\/10.1371\/journal.pone.0206100","DOI":"10.1371\/journal.pone.0206100"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Rajeh A. Amanullah S. Shivakumar K. Cole J. (2017). Interventions in ADHD: A comparative review of stimulant medications and behavioral therapies. Asian Journal of Psychiatry 25 131\u2013135. https:\/\/doi.org\/10.1016\/j.ajp.2016.09.005","DOI":"10.1016\/j.ajp.2016.09.005"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Safer D. J. (2016). Recent trends in stimulant usage. Journal of Attention Disorders 20(6) 471\u2013477. https:\/\/doi.org\/10.1177\/1087054715605915","DOI":"10.1177\/1087054715605915"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Smith K. R. Kahlon C. H. Brown J. N. Britt R. B. (2021). Methylphenidate use in geriatric depression: A systematic review. International Journal of Geriatric Psychiatry 36(9) 1304\u20131312. https:\/\/doi.org\/10.1002\/gps.5536","DOI":"10.1002\/gps.5536"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Vetter V. L. Elia J. Erickson C. Berger S. Blum N. Uzark K. Webb C. L. American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee & American Heart Association Council on Cardiovascular Nursing. (2008). Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit\/hyperactivity disorder [corrected]: A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117(18) 2407\u20132423. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.189473","DOI":"10.1161\/CIRCULATIONAHA.107.189473"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Wu L.-T. Blazer D. G. (2014). Substance use disorders and psychiatric comorbidity in mid and later life: A review. International Journal of Epidemiology 43(2) 304\u2013317. https:\/\/doi.org\/10.1093\/ije\/dyt173","DOI":"10.1093\/ije\/dyt173"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Zhang L. Li L. Andell P. Garcia-Argibay M. Quinn P. D. D\u2019Onofrio B. M. Brikell I. Kuja-Halkola R. Lichtenstein P. Johnell K. Larsson H. Chang Z. (2024). Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry 81(2) 178\u2013187. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4294","DOI":"10.1001\/jamapsychiatry.2023.4294"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251313880","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10870547251313880","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547251313880","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:30:19Z","timestamp":1777491019000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10870547251313880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10870547251313880"],"URL":"https:\/\/doi.org\/10.1177\/10870547251313880","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}